ReviewMolecular biology reports2026
Unveiling the role of p53 in the pathogenesis and treatment of autoimmune rheumatic diseases.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
p53 is a master transcription factor best known for its tumor-suppressing properties. However, its significance extends beyond cancer to the pathogenesis of autoimmune diseases. In addition to its classic effects on the cell cycle and apoptosis, mounting evidence reveals that p53 exerts various non-classical functions, including regulating immunological responses, inflammation, angiogenesis, fibrosis, and other programmed cell death modalities such as ferroptosis. Thus, p53 is critical for maintaining homeostasis and immune tolerance. Dysregulations of p53, including altered expression and mutations in individuals with autoimmune diseases, may contribute to aberrant immune responses, chronic inflammation, organ damage, and disease progression. In this review, we first briefly discuss the canonical and non-canonical functions of p53 and then explore these functions in autoimmune rheumatic disorders. The aim is to illuminate underexplored areas to guide future research that will enhance our understanding of the pathogenesis of these diseases, focusing on rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc). Lastly, we will discuss the potential of p53-based therapies, such as p53 activators, to restore normal p53 activity in autoimmune diseases, which could transform treatment options for these chronic and refractory conditions.
Indexed as
Identifiers
42663787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.